1,227
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

ORCID Icon, , , &
Pages 591-592 | Received 20 Jan 2022, Accepted 27 Jan 2022, Published online: 16 Feb 2022

We thank Feemster KA and colleagues [Citation1] for their interest in our manuscript, Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan.

The letter addresses the parameter values on vaccine efficacy (VE) and duration of immunity for PPSV23.

Regarding the VE for PPSV23, it is noteworthy that the authors of the letter have focused their comments on Invasive Pneumococcal Disease and not on Pneumococcal Pneumonia. They will know that the cost-effectiveness of pneumococcal vaccination programs is primarily and almost exclusively driven by the effectiveness of the pneumococcal vaccine against pneumococcal pneumonia. It is therefore very interesting that the authors made no reference to these parameter values in our cost-effectiveness analysis. It should be noted that in our efforts to ensure scientific balance in our analysis we used in our base case the findings of Suzuki M et al. on the effectiveness and duration of protection of Pneumovax® (PPSV23) against pneumococcal pneumonia [33.5% (5.6 to 53.1)] [Citation2] instead of the more recent analysis by Kim JH et al. [10.2% (−15.1–30.6)] [Citation3] or Heo JY et al. [11.0% (−26.4% to 37.3%)] [Citation4]. Further, in our analysis, we focused on data generated in Japan as serotype distribution, clinical practice, and research methods in Japan are most relevant for decision-making in Japan.

Regarding the duration of immunity, our analysis used the assumptions used by the National Institute for Infectious Diseases (NIID) used for the Pneumococcal Vaccines ‘Fact Sheet’ of 2018 [Citation5]. Of great concern, however, is the suggestion by the authors that they do not recognize the profound scientific credibility of NIID as they raise questions on the results of the analysis done by this institution. Further, various authors in many countries have recognized and communicated on the need for re-vaccination after 5 years acknowledging the limited protection associated with PPSV23 [Citation6–8].

There is always uncertainty in the assumptions of the parameter values in the model. Therefore, we conducted various sensitivity and scenario analyses with meaningful settings in Japan.

Declaration of interest

A Igarashi has disclosed that he received a consultant fee from Pfizer Japan, Inc., in connection with the conduct of this study. In addition, he has disclosed that he received grants from Taiho Pharmaceutical Co. Ltd., grants and other from Gilead Sciences KK., grants from Intuitive Surgical GK., grants from Boston Scientific Japan Inc., grants and personal fees from Pfizer Japan Inc., grants from Becton Dickinson and Company, grants from Milliman Inc., personal fees and other from Terumo corporation, personal fees from Chugai Pharmaceuticals Inc., personal fees from Astellas Pharma Inc., other from Fuji film Inc., other from CSL Behring Japan Inc., personal fees from Sanofi Japan Inc., personal fees and other from Takeda Pharmaceutical Inc., personal fees from Nippon Boehringer Ingelheim Inc., personal fees from Ono pharmaceutical Inc., personal fees from Novartis Pharma Japan Inc., personal fees from Eisai Inc., personal fees from AbbVie GK, personal fees from Sumitomo Dainippon Pharma Inc., personal fees from Ayumi Pharmaceutical Inc., personal fees from Medilead Inc., personal fees from Novo Nordisk Japan Inc., personal fees from GSK Japan Inc., outside the submitted work. E Hirose, Y Kobayashi, N Yonemoto and B Lee have disclosed that they are employees of Pfizer Japan Inc. and stockholders of Pfizer Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This letter was funded by Pfizer Japan Inc., Tokyo, Japan.

References

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.